Shameless cut and paste from another site but its very interesting. A test injection that maintains levels for 12 weeks..........
Current article in MD MAG.
Schering, the pharmaceutical giant, has recentlyannounce that its new testosterone depot drug "Nebido" will be sold starting in 2005 in Germany,France and the United Kingdom. The drug is already sold in Finland and its approval is Asia and Lating America is imminent. Nebido is an injectable steroid that provides an increase in, and retention of, testosterone levels. In fact,typically,hypogonadism is treated with the administration of testosterone at 100 or 200mg every other week. Nebido is designed so the injections are needed only four times per year. The difference between 26 and four injections for elavated testosterone is amazing! Same anabolic results with less discomfort; I bet this drug flies off the the legit and non-legit shelves!
Additional information
Nebido(TM) is a testosterone depot preparation, which is administered by injection. The innovative formula guarantees that the blood testosterone level remains steady and normal for a period of about twelve weeks. Until now, patients received up to twenty-two injections annually. This can be reduced to only four per year using Nebido(TM).
Hypogonadism is an indication of reduced testosterone formation because of underactive testes, which lowers the concentration of this most important male sexual hormone in the blood. Testosterone deficiency can lead to severe health problems and considerably impair quality of life. Various symptoms can be observed, depending on the man's age and how long the hormone deficiency has persisted. These include for example: fatigue, loss of energy, impotence and loss of libido, anemia and osteoporosis.
There are many different causes of testosterone deficiency. It is often due to congenital disorders related to hormonal feedback regulation between the brain and the testicles, or the result of testicular diseases; it may also be caused by a general decrease in gonadal function due to aging. Testosterone deficiency can be treated using hormone preparations. Once the testosterone level has returned to normal, health and quality-of-life immediately improve for those affected by the disorder.
In November 2003, Finland became the first European country to approve Nebido(TM). Approval in Latin America and Asia is expected in 2005. Approval for the new European Countries is aimed for in a second Mutual Recognition Procedure.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology & Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Current article in MD MAG.
Schering, the pharmaceutical giant, has recentlyannounce that its new testosterone depot drug "Nebido" will be sold starting in 2005 in Germany,France and the United Kingdom. The drug is already sold in Finland and its approval is Asia and Lating America is imminent. Nebido is an injectable steroid that provides an increase in, and retention of, testosterone levels. In fact,typically,hypogonadism is treated with the administration of testosterone at 100 or 200mg every other week. Nebido is designed so the injections are needed only four times per year. The difference between 26 and four injections for elavated testosterone is amazing! Same anabolic results with less discomfort; I bet this drug flies off the the legit and non-legit shelves!
Additional information
Nebido(TM) is a testosterone depot preparation, which is administered by injection. The innovative formula guarantees that the blood testosterone level remains steady and normal for a period of about twelve weeks. Until now, patients received up to twenty-two injections annually. This can be reduced to only four per year using Nebido(TM).
Hypogonadism is an indication of reduced testosterone formation because of underactive testes, which lowers the concentration of this most important male sexual hormone in the blood. Testosterone deficiency can lead to severe health problems and considerably impair quality of life. Various symptoms can be observed, depending on the man's age and how long the hormone deficiency has persisted. These include for example: fatigue, loss of energy, impotence and loss of libido, anemia and osteoporosis.
There are many different causes of testosterone deficiency. It is often due to congenital disorders related to hormonal feedback regulation between the brain and the testicles, or the result of testicular diseases; it may also be caused by a general decrease in gonadal function due to aging. Testosterone deficiency can be treated using hormone preparations. Once the testosterone level has returned to normal, health and quality-of-life immediately improve for those affected by the disorder.
In November 2003, Finland became the first European country to approve Nebido(TM). Approval in Latin America and Asia is expected in 2005. Approval for the new European Countries is aimed for in a second Mutual Recognition Procedure.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology & Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.

Please Scroll Down to See Forums Below 











